Detalhe da pesquisa
1.
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
Blood
; 132(10): 1050-1063, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29997223
2.
Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Clin Cancer Res
; 30(10): 2288, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38745477
3.
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.
J Hematol Oncol
; 11(1): 63, 2018 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29739426
4.
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Leukemia
; 32(9): 1948-1957, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29487387
5.
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.
Oncotarget
; 8(63): 106527-106537, 2017 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29290968
6.
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Clin Cancer Res
; 22(5): 1222-33, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26527748
7.
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Mol Cancer Ther
; 15(6): 1364-75, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27196750